At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
At a recent Abbott-sponsored satellite symposium held during the GUT Congress 2016 in Kuala Lumpur, an expert from India presented on the management of alcoholic liver disease, and illustrated the role of SAMe as a complementary therapy.
In this edition of MIMS Hepatology, we bring you recent updates in the treatment of hepatitis C, as well as highlights from two lectures presented in conjunction with the launch of Harvoni® (ledipasvir/sofosbuvir; LF Asia).
At a recent Abbott-sponsored symposium during the 11th Liver Update 2015, Professor José Mato discussed the role of S-adenosylmethionine (SAMe) in liver diseases. The following are highlights from his talk.
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors.
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Hepatology - Malaysia digital copy today!
Adjunct boceprevir is effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
Over one-third of patients with prior hepatitis B virus (HBV) exposure had HBV reactivation 2 years after haematopoietic stem cell transplantation (HSCT), according to a study by The University of Hong Kong (HKU).